Why I’d buy into the biotech revolution with AstraZeneca plc, Roche Holding Ltd. and Amgen, Inc.

AstraZeneca plc (LON:AZN), Roche Holding Ltd. (VTX:RHHBY) and Amgen, Inc. (NASDAQ:AMGN) are 3 plays on a new healthcare boom.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The first age of the pharmaceutical industry ran from the 1960s to the early years of this century. It was the age of the chemical drug. These drugs are chemical compounds, that had been found to have a beneficial effect on the human body and which were synthesized in the laboratory.

Think of paracetamol, Lipitor (atorvastatin) and Viagra (sildenafil). This led to the first boom in the drugs industry, when patent-protected blockbuster medicines made billions of pounds for these firms. Yet recently we have seen a decline in this industry, with a series of key patent expiries, and declining profits as more as more doctors and patients turned to generic medicines.

The second age of pharmaceuticals has begun

But reports of the demise of the pharmaceutical industry have been greatly exaggerated. That’s because we are now at the beginning of the second age of the healthcare sector — the age of biotechnology.

In research laboratories from Oxford and Harvard, to ETH and Stanford, scientists are coming up with new innovations in the biosciences. Papers and patents are being published, spin-out companies created and new products are being devised and launched.

The innovations are coming in many different areas. Genetics and gene sequencing are yielding a huge amount of information about how our bodies function. Stem cell science will lead to the hope that the paralysed will be able to walk again, and that replacement organs can be grown. The science of vaccines means that we are protected from many common diseases. And the development of antibody-based biological drugs means that cancer is a disease that finally can be defeated.

A great time to invest in biotech

In the UK, I think the leader in these new treatments is AstraZeneca (LSE: AZN), a drugs company that has set out its stall to be a world-leading innovator in healthcare. A recent pull back in the share means that, at a 2016 P/E ratio of 13.61, and with a dividend yield of 5.14%, this firm offers good value.

In Switzerland, another pharma company with a similar outlook to AstraZeneca is Roche (NASDAQOTH:RHHBY). It also has substantial strengths in biotech and produces a range of drugs including anti-cancer treatments Avastin and Herceptin. It is a highly acquisitive firm that has taken over many biotech businesses, including Genentech. It is highly rated, with a P/E ratio of 24.06, and a dividend yield of 3.22%, but, to many investors and analysts, it represents as clear a vision as you can get of the future of pharma.

In the US, the leading biotech firm is Amgen (NASDAQ:AMGN). Headquartered in Thousand Oaks, California, you might be surprised to hear that its $116bn valuation makes it worth more than AstraZeneca. Like Roche, it buys up promising spin-out businesses so that it can remain at the cutting edge of this fast-moving industry.

It produces treatments for arthritis, anaemia and osteoporosis. And it is a firm that is steadily growing revenues and earnings. A P/E ratio of 16.92, with a dividend yield of 2.31%, means you can buy into growth at a reasonable price, and the scale of this business means it is nowhere near as risky as taking a punt on a small cap biotech start-up.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will it be too late to buy Nvidia stock in March?

NVIDIA stock is up more than 60% since the start of 2024. Our writer considers whether it might still be…

Read more »

Typical street lined with terraced houses and parked cars
Investing Articles

Why did Direct Line shares just soar 27%?

Direct Line shares have jumped more than a quarter in the course of today's trading session. Our writer explains why…

Read more »

Close-up of British bank notes
Investing Articles

These 2 shares are Dividend Aristocrats. Which should I buy this March?

Our writer likes the business model of this pair of FTSE 100 Dividend Aristocrats. So why would he only consider…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

I bought 49 Unilever shares in June. Here’s what they’re worth today

Harvey Jones bought a modest amount of Unilever shares last summer hoping the stock would soon recover. He's having to…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

I reckon these shares, potentially 20% undervalued, are Warren Buffett’s type of investment

Oliver Rodzianko thinks Games Workshop is an absolutely stellar investment. As it's potentially undervalued, he reckons Warren Buffett would agree.

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Great investing habits that can boost my Stocks and Shares ISA

Forget complicated calculations and financial jargon! Our writer uses a few simple habits to build wealth inside his Stocks and…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Why has the St. James’s Place share price crashed 30%, after FY results?

The St. James's Place share price has just fallen off a cliff. What could have gone wrong in 2023 that's…

Read more »

Family in protective face masks in airport
Investing Articles

Here’s how much I’d have if I’d bought 1,000 Rolls-Royce shares 10 years ago

Rolls-Royce shares may be flying high this year but that wasn't always the case. I'm calculating how much I'd have…

Read more »